TSBX(Delisted)
Turnstone Biologics·NASDAQ
--
--(--)
TSBX fundamentals
During Q2 2025, Turnstone Biologics (TSBX) reported revenue of --, a YoY change of 0.00%. Net income was -5.49M, a YoY change of 74.23%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | TTM |
|---|
Start Date | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | -- |
End Date | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 10.72M -- | 41.91M -- | 10.22M -- | 10.45M -- | 19.31M +80.13% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | 10.72M -- | 41.91M -- | 10.22M -- | 10.45M -- | 19.31M +80.13% | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | 10.72M -- | 41.91M -- | 10.22M -- | 10.45M -- | 19.31M +80.13% | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 23.40M -- | 30.47M -- | 26.49M -- | 24.57M -- | 19.70M -15.81% | 21.85M -28.28% | 18.93M -28.54% | 17.86M -27.32% | 20.69M +5.03% | 22.06M +0.94% | 18.37M -2.97% | -- -- | -- -- | -- -- | -- -- |
Selling, General and Administrative Expenses | 4.70M -- | 3.93M -- | 5.24M -- | 4.35M -- | 4.03M -14.18% | 4.66M +18.49% | 4.76M -9.20% | 4.40M +1.03% | 4.90M +21.55% | 4.33M -7.13% | 3.94M -17.11% | -- -- | -- -- | -- -- | -- -- |
Research and Development Expenses | 18.70M -- | 26.54M -- | 21.25M -- | 20.21M -- | 15.67M -16.22% | 17.19M -35.21% | 14.17M -33.31% | 13.46M -33.42% | 15.79M +0.78% | 17.73M +3.12% | 14.42M +1.78% | -- -- | -- -- | -- -- | -- -- |
Operating Income | -12.68M -- | 11.45M -- | -16.27M -- | -14.12M -- | -394.00K +96.89% | -21.85M -290.91% | -18.93M -16.34% | -17.86M -26.46% | -20.69M -5151.52% | -22.06M -0.94% | -18.37M +2.97% | -- -- | -- -- | -- -- | -- -- |
Non-Operating Income (Loss) | 85.00K -- | 180.00K -- | 200.00K -- | 468.00K -- | 380.00K +347.06% | 347.00K +92.78% | 1.58M +689.00% | 1.24M +165.17% | 1.08M +183.68% | 755.00K +117.58% | 520.00K -67.05% | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | 85.00K -- | 180.00K -- | 200.00K -- | 468.00K -- | 380.00K +347.06% | 347.00K +92.78% | 1.58M +689.00% | 1.24M +165.17% | 1.08M +183.68% | 755.00K +117.58% | 520.00K -67.05% | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -12.60M -- | 11.63M -- | -16.07M -- | -13.65M -- | -14.00K +99.89% | -21.50M -284.97% | -17.35M -7.97% | -16.61M -21.70% | -19.61M -139992.86% | -21.30M +0.94% | -17.85M -2.86% | -12.04M +27.55% | -11.80M +39.82% | -5.48M +74.28% | -47.17M -- |
Income Tax Expense | 20.00K -- | 26.00K -- | 80.00K -- | 15.00K -- | -82.00K -510.00% | -6.00K -123.08% | -33.00K -141.25% | -165.00K -1200.00% | 16.00K +119.51% | 2.00K +133.33% | -816.00K -2372.73% | 835.00K +606.06% | 2.00K -87.50% | 12.00K +500.00% | 33.00K -- |
Net Income | -12.62M -- | 11.60M -- | -16.15M -- | -13.67M -- | 68.00K +100.54% | -21.50M -285.34% | -17.32M -7.23% | -16.45M -20.36% | -19.63M -28966.18% | -21.30M +0.91% | -17.03M +1.66% | -12.87M +21.75% | -11.81M +39.85% | -5.49M +74.23% | -47.20M -- |
Net Income Attributable to Owners of the Company | -12.62M -- | 11.60M -- | -16.15M -- | -13.67M -- | 68.00K +100.54% | -21.50M -285.34% | -17.32M -7.23% | -16.45M -20.36% | -19.63M -28966.18% | -21.30M +0.91% | -17.03M +1.66% | -- -- | -- -- | -- -- | -- -- |
Preferred Stock Dividends | 57.00K -- | 57.00K -- | 57.00K -- | 19.00K -- | 20.00K -64.91% | 19.00K -66.67% | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Adjustments | -- -- | 10.36M -- | -- -- | -- -- | 48.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -12.67M -- | 1.19M -- | -16.21M -- | -13.69M -- | 0 +100.00% | -21.52M -1911.28% | -17.32M -6.85% | -16.45M -20.20% | -19.63M -- | -21.30M +0.99% | -17.03M +1.66% | -- -- | -- -- | -- -- | -- -- |
Other Comprehensive Income | -94.00K -- | -81.00K -- | -65.00K -- | 72.00K -- | 121.00K +228.72% | 59.00K +172.84% | -8.00K +87.69% | 122.00K +69.44% | -117.00K -196.69% | 10.00K -83.05% | 30.00K +475.00% | -6.00K -104.92% | -- -- | -- -- | -- -- |
Total Comprehensive Income | -12.71M -- | 11.52M -- | -16.22M -- | -13.60M -- | 189.00K +101.49% | -21.44M -286.13% | -17.33M -6.85% | -16.33M -20.10% | -19.75M -10547.62% | -21.29M +0.68% | -17.00M +1.88% | -12.88M +21.13% | -11.81M +40.21% | -5.49M +74.22% | -47.18M -- |
Total Comprehensive Income Attributable to Owners of the Company | -12.71M -- | 11.52M -- | -16.22M -- | -13.60M -- | 189.00K +101.49% | -21.44M -286.13% | -17.33M -6.85% | -16.33M -20.10% | -19.75M -10547.62% | -21.29M +0.68% | -17.00M +1.88% | -- -- | -- -- | -- -- | -- -- |
Basic EPS | -5.56 -- | 0.5 -- | -6.15 -- | -- -- | 0 +100.00% | -7.56 -1612.00% | -1 +83.74% | -0.71 -- | -0.85 -- | -0.92 +87.83% | -0.74 +26.00% | -0.56 +21.13% | -0.51 +40.00% | -0.24 +73.91% | -2.05 -- |
Diluted EPS | -5.56 -- | 0.42 -- | -6.15 -- | -- -- | 0 +100.00% | -7.56 -1900.00% | -1 +83.74% | -- -- | -0.85 -- | -0.92 +87.83% | -0.74 +26.00% | -- -- | -0.51 +40.00% | -0.24 +73.91% | -- -- |
You can ask Aime
No Data
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
